Significant Decreasing Incidence of Encapsulating Peritoneal Sclerosis in the Dutch Population of Peritoneal Dialysis Patients

Betjes, Michiel G. H.; Habib, Sayed M.; Boeschoten, Els W.; Hemke, Aline C.; Struijk, D. G.; Westerhuis, Ralph; Abrahams, Alferso C; Korte, Mario R.

doi:10.3747/pdi.2016.00109

Cited by 29 publications

(22 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Genetic variation in the receptor for AGEs might predispose to peritoneal deterioration [92]. Mortality approaches about 50% at 1 year after diagnosis of EPS in PD patients [90,93]. The rarity of the disorder, its variable presentation, and the lack of screening tools frequently lead to diagnosis being delayed.…”

Section: Encapsulating Peritoneal Sclerosismentioning

confidence: 99%

Proteomic Research in Peritoneal Dialysis

Bonomini

Borràs

Troya-Saborido

et al. 2020

IJMS

View full text Add to dashboard Cite

Peritoneal dialysis (PD) is an established home care, cost-effective renal replacement therapy (RRT), which offers several advantages over the most used dialysis modality, hemodialysis. Despite its potential benefits, however, PD is an under-prescribed method of treating uremic patients. Infectious complications (primarily peritonitis) and bio-incompatibility of PD solutions are the main contributors to PD drop-out, due to their potential for altering the functional and anatomical integrity of the peritoneal membrane. To improve the clinical outcome of PD, there is a need for biomarkers to identify patients at risk of PD-related complications and to guide personalized interventions. Several recent studies have shown that proteomic investigation may be a powerful tool in the prediction, early diagnosis, prognostic assessment, and therapeutic monitoring of patients on PD. Indeed, analysis of the proteome present in PD effluent has uncovered several proteins involved in inflammation and pro-fibrotic insult, in encapsulating peritoneal sclerosis, or even in detecting early changes before any measurable modifications occur in the traditional clinical parameters used to evaluate PD efficacy. We here review the proteomic studies conducted thus far, addressing the potential use of such omics methodology in identifying potential new biomarkers of the peritoneal membrane welfare in relation to dialytic prescription and adequacy.

show abstract

Section: Encapsulating Peritoneal Sclerosismentioning

confidence: 99%

Proteomic Research in Peritoneal Dialysis

Bonomini

Borràs

Troya-Saborido

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…Promisingly, the annual incidence of EPS is decreasing. A Dutch study reported a remarkable decrease in the annual incidence of EPS from 0.85% in 2009 to 0.14% in 2014 [22]. This decrease can be attributed to advances of PD techniques, use of physiological PD solutions (e.g., neutral solutions with low glucose degradation products), and availability of expert training to prevent peritonitis [23,24].…”

Section: Discussionmentioning

confidence: 99%

“…In EPS management, developing a systemized protocol to detect and treat EPS in the early phase is important [25]. Tamoxifen with or without steroids in the early phase of EPS could be beneficial for inhibiting progression to severe EPS or recurrence [22,26].…”

Section: Discussionmentioning

confidence: 99%

Outcomes of the surgical management of encapsulating peritoneal sclerosis: A case series from a single center in Korea

Ryu

Lee

Koo

et al. 2019

Kidney Res Clin Pract

View full text Add to dashboard Cite

BackgroundEncapsulating peritoneal sclerosis (EPS) is a rare but near-fatal complication of peritoneal dialysis (PD). Despite the high mortality rate of EPS, the surgical treatment strategy of severe EPS is yet to be established.MethodsWe retrospectively analyzed outcomes of patients with EPS who underwent enterolysis for intractable EPS at Seoul National University Hospital between 2001 and 2018. EPS was diagnosed based on the clinical symptoms and radiological findings of abdominal computed tomography (CT). CT scans were scored according to an EPS scoring system that assessed peritoneal thickening and calcification as well as bowel thickening, tethering, loculation, and dilatation.ResultsThirteen patients (nine males and four females; age, 48 [29–63] years) underwent enterolysis for severe EPS. PD duration (11 [6–21] years) was not associated with survival. Two patients were newly diagnosed with EPS following kidney transplantation. Five patients died of infectious complications immediately after the surgery. Eight patients survived after the first surgery; however, five of them underwent reoperation but died of persistent infection, fistula formation, or adhesive bowel obstruction. Four young (< 60 years) male patients with relatively low CT scan scores (< 13) survived for > 2 years after the first surgery. Median survival duration from EPS diagnosis was 22 (1.3–184) months and that from the first surgery was 9 (0.3–153) months.ConclusionThe high mortality rate of EPS suggests the importance of appropriate surgical intervention in young symptomatic male EPS patients with relatively low CT scan scores.

show abstract

“…Around the globe centres reported a variable incidence ranging between 0.8 and 19.4% which may be increasing along with the PD duration (22,24). A recent Dutch study showed a decrease in incidence from 0.85 in 2009 to 0.14 in 2014 without a decrease number of patients on PD (25).…”

Section: Discussionmentioning

confidence: 99%